Display options
Cite
Narod SA, Tung N, Lubinski J, et al. A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. Curr Oncol. 2014;21(2):64-8doi: 10.3747/co.21.1656.
Narod, S. A., Tung, N., Lubinski, J., Huzarski, T., Robson, M., Lynch, H. T., Neuhausen, S. L., Ghadirian, P., Kim-Sing, C., Sun, P., Foulkes, W. D. (2014). A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. Current oncology (Toronto, Ont.), 21(2), 64-8. https://doi.org/10.3747/co.21.1656
Narod, S A, et al. "A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers." Current oncology (Toronto, Ont.) vol. 21,2 (2014): 64-8. doi: https://doi.org/10.3747/co.21.1656
Narod SA, Tung N, Lubinski J, Huzarski T, Robson M, Lynch HT, Neuhausen SL, Ghadirian P, Kim-Sing C, Sun P, Foulkes WD. A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. Curr Oncol. 2014 Apr;21(2):64-8. doi: 10.3747/co.21.1656. PMID: 24764694; PMCID: PMC3997444.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2014 Apr;21(2):64-8. doi: 10.3747/co.21.1656.

A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.

Current oncology (Toronto, Ont.)

S A Narod, N Tung, J Lubinski, T Huzarski, M Robson, H T Lynch, S L Neuhausen, P Ghadirian, C Kim-Sing, P Sun, W D Foulkes,

Affiliations

  1. Women's College Research Institute, University of Toronto, Toronto, ON.
  2. Beth Israel Deaconness Hospital, Boston, MA, U.S.A.
  3. Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
  4. Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York City, NY, U.S.A.
  5. Department of Preventive Medicine, Creighton University, Omaha, NE, U.S.A.
  6. Beckman Research Institute of the City of Hope, Duarte, CA, U.S.A.
  7. Epidemiology Research Unit, CHUM-Hôtel-Dieu, Montreal, QC.
  8. BC Cancer Agency, Vancouver, BC.
  9. Departments of Medical Genetics and Oncology, McGill University, Montreal, QC.

PMID: 24764694 PMCID: PMC3997444 DOI: 10.3747/co.21.1656

Abstract

BACKGROUND: The risk of breast cancer in carriers of BRCA1 and BRCA2 mutations is influenced by factors other than the genetic mutation itself. Modifying factors include a woman's reproductive history and family history of cancer. Risk factors are more likely to be present in women with breast cancer than in women without breast cancer, and therefore the risk of cancer in the two breasts should not be independent. It is not clear to what extent modifying factors influence the risk of a first primary or a contralateral breast cancer in BRCA carriers.

METHODS: We conducted a matched case-control study of breast cancer among 3920 BRCA1 or BRCA2 mutation carriers. We asked whether a past history of breast cancer in the contralateral breast was a risk factor for breast cancer.

RESULTS: After adjustment for age, country of residence, and cancer treatment, a previous cancer of the right breast was found to be a significant risk factor for cancer of the left breast among BRCA1 or BRCA2 carriers (relative risk: 2.1; 95% confidence interval: 1.4 to 3.0; p < 0.0001).

CONCLUSIONS: In a woman with a BRCA1 or BRCA2 mutation who is diagnosed with breast cancer, the risk of cancer in the contralateral breast depends on the first diagnosis. That observation supports the hypothesis that there are important genetic or non-genetic modifiers of cancer risk in BRCA carriers. Discovering risk modifiers might lead to greater personalization of risk assessment and management recommendations for BRCA-positive patients.

Keywords: BRCA1; BRCA2; contralateral breast cancer

References

  1. J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8 - PubMed
  2. Lancet. 1994 Mar 19;343(8899):692-5 - PubMed
  3. Int J Cancer. 2012 Jul 1;131(1):229-34 - PubMed
  4. J Clin Oncol. 2007 Sep 20;25(27):4210-6 - PubMed
  5. BMJ. 2014 Feb 11;348:g226 - PubMed
  6. J Natl Cancer Inst. 2013 Jun 5;105(11):812-22 - PubMed
  7. Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1534-8 - PubMed
  8. J Natl Cancer Inst. 2002 Aug 21;94(16):1221-6 - PubMed
  9. J Natl Cancer Inst. 2010 Dec 15;102(24):1874-8 - PubMed
  10. J Clin Oncol. 2005 Oct 20;23(30):7491-6 - PubMed
  11. J Clin Oncol. 2004 Jun 15;22(12):2328-35 - PubMed
  12. Lancet. 1999 Nov 27;354(9193):1846-50 - PubMed
  13. Lancet. 1993 Apr 24;341(8852):1101-2 - PubMed
  14. Am J Hum Genet. 2003 May;72(5):1117-30 - PubMed
  15. Cancer Causes Control. 2005 Aug;16(6):667-74 - PubMed
  16. J Med Genet. 2002 Jun;39(6):407-9 - PubMed

Publication Types